WO2014167435A3 - Liposomal pharmaceutical formulations for enhanced drug delivery - Google Patents

Liposomal pharmaceutical formulations for enhanced drug delivery Download PDF

Info

Publication number
WO2014167435A3
WO2014167435A3 PCT/IB2014/059991 IB2014059991W WO2014167435A3 WO 2014167435 A3 WO2014167435 A3 WO 2014167435A3 IB 2014059991 W IB2014059991 W IB 2014059991W WO 2014167435 A3 WO2014167435 A3 WO 2014167435A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug delivery
pharmaceutical formulations
liposomes
enhanced drug
tpgs
Prior art date
Application number
PCT/IB2014/059991
Other languages
French (fr)
Other versions
WO2014167435A2 (en
Inventor
Sarvesh MALVIYA
Original Assignee
Malviya Sarvesh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Malviya Sarvesh filed Critical Malviya Sarvesh
Publication of WO2014167435A2 publication Critical patent/WO2014167435A2/en
Publication of WO2014167435A3 publication Critical patent/WO2014167435A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided is a development and characterization of the D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) surface functionalized liposome formulation for enhanced tumor delivery of docetaxel. The presence of TPGS surface coating on liposomes provided enhanced circulation half life, superior antitumor efficacy and safety profile as compared to commercial formulation (Taxotere), PEGylated liposomes, conventional liposomes and free drug.
PCT/IB2014/059991 2013-04-10 2014-03-20 Liposomal pharmaceutical formulations for enhanced drug delivery WO2014167435A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1086DE2013 2013-04-10
IN1086/DEL/2013 2013-04-10

Publications (2)

Publication Number Publication Date
WO2014167435A2 WO2014167435A2 (en) 2014-10-16
WO2014167435A3 true WO2014167435A3 (en) 2015-02-19

Family

ID=51690076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/059991 WO2014167435A2 (en) 2013-04-10 2014-03-20 Liposomal pharmaceutical formulations for enhanced drug delivery

Country Status (1)

Country Link
WO (1) WO2014167435A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170165200A1 (en) * 2015-11-20 2017-06-15 University Of North Texas Health Science Center Composition of lipid-based nanoparticles for small molecules and macromolecules
KR20200093534A (en) 2017-11-30 2020-08-05 실파 메디케어 리미티드 Docetaxel liposome injection composition with high drug loading properties
CN110698663A (en) * 2018-07-10 2020-01-17 江西联陆生物科技有限公司 Method for synthesizing water-soluble vitamin E polyethylene glycol succinate in vacuum-pumping solvent-free mode
US11857680B2 (en) 2018-11-26 2024-01-02 Shilpa Medicare Limited Composition of docetaxel liposomal injection with high drug loading
WO2023041588A1 (en) 2021-09-14 2023-03-23 Advapharm Gmbh Novel lipopeptide formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089931A1 (en) * 2006-02-01 2007-08-09 Sd Pharmaceuticals, Inc. Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2009092291A1 (en) * 2008-01-16 2009-07-30 Shenyang Pharmaceutical University A drug delivery system, its preparation process and use
CN101991538A (en) * 2009-08-14 2011-03-30 浙江工业大学 TPGS-containing liposome composition and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089931A1 (en) * 2006-02-01 2007-08-09 Sd Pharmaceuticals, Inc. Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2009092291A1 (en) * 2008-01-16 2009-07-30 Shenyang Pharmaceutical University A drug delivery system, its preparation process and use
CN101991538A (en) * 2009-08-14 2011-03-30 浙江工业大学 TPGS-containing liposome composition and application thereof

Also Published As

Publication number Publication date
WO2014167435A2 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
WO2014167435A3 (en) Liposomal pharmaceutical formulations for enhanced drug delivery
MX2015012201A (en) Modified docetaxel liposome formulations.
WO2015184127A3 (en) Stable cannabinoid formulations
AU2016343803A8 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
BR112014009305A2 (en) freeze-dried liposomes
TR201816986T4 (en) Lipids for therapeutic agent delivery formulations.
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
WO2014057432A3 (en) Multicomponent lipid nanoparticles and processes for the preparation thereof
NZ701573A (en) Carriers for improved drug delivery
WO2012091523A8 (en) Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
MX2015012200A (en) Liposome oxaliplatin compositions for cancer therapy.
RU2020137384A (en) TUMOR TREATMENT AND SET CONTAINING LIPOSOMAL COMPOSITION OF HEMCITABIN
WO2012135422A3 (en) Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics
WO2012021107A3 (en) A liposomal formulation for ocular drug delivery
WO2014121291A3 (en) Nanoparticle drug delivery systems
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
CL2015000418A1 (en) Topical aqueous formulation comprising an antiangiogenic drug that is an anti-vegf antibody and a liposome formed from a peg-based lipid; its use in the treatment of a disease or condition related to vegf; and method to treat cancer, psoriasis and diabetic macular edema, among other diseases.
MX2015012199A (en) Liposomal cisplatin compositions for cancer therapy.
BR112017007076A2 (en) 17a, 21-Cortexolone diesters for use in tumor treatment
DK201270677A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MY172310A (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
EP3528820A4 (en) Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
WO2012040331A3 (en) Multistage nanoparticles
WO2014197991A8 (en) Compounds for promoting liposomal and cellular adhesion and compositions and methods of use thereof

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14782471

Country of ref document: EP

Kind code of ref document: A2